AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
estradiol acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| estrogens | 4497 | 4245-41-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 0.01 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 5 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.624 | Moderate | 0.77 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.944 | Moderate | 0.77 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 24.155 | 10^-6 cm/s | Moderate | 0.77 |
| dh-clint | Dog hepatocyte intrinsic clearance | 164.059 | uL/min/10^6 cells | Moderate | 0.77 |
| dppb | Dog plasma protein binding (% unbound) | 1.840 | % | Moderate | 0.77 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 2.090 | % | Moderate | 0.77 |
| herg | hERG pIC50 | 4.635 | pIC50 | Moderate | 0.77 |
| hh-clint | Human hepatocyte intrinsic clearance | 301.995 | uL/min/10^6 cells | Moderate | 0.77 |
| hlm-clint | Human liver microsomal intrinsic clearance | 158.855 | uL/min/mg protein | Moderate | 0.77 |
| hppb | Human plasma protein binding (% unbound) | 1.340 | % | Moderate | 0.77 |
| kinase-safety-class | ACVR2B,BRAF,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,NTRK2,PDK1,PDK2,PDK4,PRKDC,TGFBR1 | 14 | |||
| kinase-selectivity-class | EIF2AK3 | 1 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.959 | Moderate | 0.77 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 341.979 | Moderate | 0.77 | |
| mppb | Mouse plasma protein binding (% unbound) | 2.510 | Moderate | 0.77 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 2.399 | Moderate | 0.77 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 4.040 | % | Moderate | 0.77 |
| rh-clint | Rat hepatocyte intrinsic clearance | 317.687 | uL/min/10^6 cells | Moderate | 0.77 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 22.910 | % | Moderate | 0.77 |
| rppb | Rat plasma protein binding (% unbound) | 2.690 | % | Moderate | 0.77 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 15.488 | uM | Moderate | 0.77 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 20, 2003 | FDA | WARNER IRELAND |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Therapeutic product effect decreased | 153.34 | 48.43 | 48 | 216 | 277523 | 90350660 |
| Drug ineffective | 53.60 | 48.43 | 38 | 226 | 1384260 | 89243923 |
| Hot flush | 52.51 | 48.43 | 15 | 249 | 59473 | 90568710 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA CS | M0447348 | Estradiol Congeners |
| FDA MoA | N0000000100 | Estrogen Receptor Agonists |
| MeSH PA | D004967 | Estrogens |
| MeSH PA | D006728 | Hormones |
| FDA EPC | N0000175825 | Estrogen |
| CHEBI has role | CHEBI:50114 | estrogen |
| CHEBI has role | CHEBI:77746 | human metabolite |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Atrophic vaginitis | indication | 52441000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Estrogen receptor | Nuclear hormone receptor | AGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D04061 | KEGG_DRUG |
| 4025444 | VUID |
| N0000175999 | NUI |
| 4017609 | VANDF |
| 4021205 | VANDF |
| 4025444 | VANDF |
| CHEBI:135981 | CHEBI |
| EST | PDB_CHEM_ID |
| CHEMBL1200430 | ChEMBL_ID |
| DB13952 | DRUGBANK_ID |
| 5R97F5H93P | UNII |
| DB00783 | DRUGBANK_ID |
| 405416 | RXNORM |
| 17173 | MMSL |
| 4684 | MMSL |
| 6157 | MMSL |
| 73244 | MMSL |
| 8602 | MMSL |
| d00537 | MMSL |
| 001265 | NDDF |
| 009983 | NDDF |
| 126172005 | SNOMEDCT_US |
| 12839006 | SNOMEDCT_US |
| 414140005 | SNOMEDCT_US |
| C1330622 | UMLSCUI |
| C0014912 | UMLSCUI |
| 9818306 | PUBCHEM_CID |
| 5757 | PUBCHEM_CID |
| 406 | INN_ID |
| D004958 | MESH_DESCRIPTOR_UI |
| CHEBI:16469 | CHEBI |
| 5R97F5H93P | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Femring | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6030 | RING | 0.10 mg | VAGINAL | NDA | 15 sections |
| Femring | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72495-201 | RING | 0.05 mg | VAGINAL | NDA | 31 sections |
| Femring | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72495-202 | RING | 0.10 mg | VAGINAL | NDA | 31 sections |